Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Kastrup, J; Jorgensen, E; Drvota, V
   Vascular growth factor and gene therapy to induce new vessels in the ischemic myocardium: Therapeutic angiogenesis
   SCANDINAVIAN CARDIOVASCULAR JOURNAL
   
   J. Kastrup et al., "Vascular growth factor and gene therapy to induce new vessels in the ischemic myocardium: Therapeutic angiogenesis", SC CARDIOVA, 35(5), 2001, pp. 291-296
2. Sylven, C; Sarkar, N; Ruck, A; Drvota, V; Y-Hassan, S; Lind, B; Nygren, A; Kallner, G; Blomberg, P; van der Linden, J; Lindblom, D; Brodin, LA; Islam, KB
   Myocardial Doppler tissue velocity improves following myocardial gene therapy with VEGF-A(165) plasmid in patients with inoperable angina pectoris
   CORONARY ARTERY DISEASE
   
   C. Sylven et al., "Myocardial Doppler tissue velocity improves following myocardial gene therapy with VEGF-A(165) plasmid in patients with inoperable angina pectoris", CORON ART D, 12(3), 2001, pp. 239-243
3. Sarkar, N; Ruck, A; Kallner, G; Y-Hassan, S; Blomberg, P; Islam, KB; Van Der Linden, J; Lindblom, D; Nygren, AT; Lind, B; Brodin, LA; Drvota, V; Sylven, C
   Effects of intramyocardial injection of phVEGF-A(165) as sole therapy in patients with refractory coronary artery disease - 12-month follow-up: Angiogenic gene therapy
   JOURNAL OF INTERNAL MEDICINE
   
   N. Sarkar et al., "Effects of intramyocardial injection of phVEGF-A(165) as sole therapy in patients with refractory coronary artery disease - 12-month follow-up: Angiogenic gene therapy", J INTERN M, 250(5), 2001, pp. 373-381
4. Sylven, C; Sarkar, N; Wardell, E; Jamsa, A; Drvota, V; Blomberg, P; Bin Islam, K
   Protein and angiogenic dose-response expression of phVEGF-A(165) gene in rat myocardium
   JOURNAL OF THROMBOSIS AND THROMBOLYSIS
   
   C. Sylven et al., "Protein and angiogenic dose-response expression of phVEGF-A(165) gene in rat myocardium", J THROMB TH, 12(2), 2001, pp. 151-156
5. Hellgren, I; Drvota, V; Pieper, R; Enoksson, S; Blomberg, P; Islam, KB; Sylven, C
   Highly efficient cell-mediated gene transfer using non-viral vectors and FuGene (TM) 6: in vitro and in vivo studies
   CELLULAR AND MOLECULAR LIFE SCIENCES
   
   I. Hellgren et al., "Highly efficient cell-mediated gene transfer using non-viral vectors and FuGene (TM) 6: in vitro and in vivo studies", CELL MOL L, 57(8-9), 2000, pp. 1326-1333
6. Shahrara, S; Silven, C; Drvota, V
   Subtype specific downregulation of thyroid hormone receptor mRNA by beta-adrenoreceptor blockade in the myocardium
   BIOLOGICAL & PHARMACEUTICAL BULLETIN
   
   S. Shahrara et al., "Subtype specific downregulation of thyroid hormone receptor mRNA by beta-adrenoreceptor blockade in the myocardium", BIOL PHAR B, 23(11), 2000, pp. 1303-1306
7. Shahrara, S; Drvota, V; Sylven, C
   Organ specific expression of thyroid hormone receptor mRNA and protein in different human tissues
   BIOLOGICAL & PHARMACEUTICAL BULLETIN
   
   S. Shahrara et al., "Organ specific expression of thyroid hormone receptor mRNA and protein in different human tissues", BIOL PHAR B, 22(10), 1999, pp. 1027-1033
8. Shahrara, S; Drvota, V
   Thyroid hormone alpha(1) and beta(1) receptor mRNA are downregulated by amiodarone in mouse myocardium
   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
   
   S. Shahrara e V. Drvota, "Thyroid hormone alpha(1) and beta(1) receptor mRNA are downregulated by amiodarone in mouse myocardium", J CARDIO PH, 34(2), 1999, pp. 261-267
9. Drvota, V; Haggblad, J; Blange, I; Magnusson, Y; Sylven, S
   The effect of amiodarone on the beta-adrenergic receptor is due to a downregulation of receptor protein and not to a receptor-ligand interaction
   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
   
   V. Drvota et al., "The effect of amiodarone on the beta-adrenergic receptor is due to a downregulation of receptor protein and not to a receptor-ligand interaction", BIOC BIOP R, 255(2), 1999, pp. 515-520
10. Shahrara, S; Tidholm, A; Drvota, V; Haggstom, J; Sylven, C
    Upregulation of thyroid hormone receptor beta(1) and beta(2) messenger RNAin the myocardium of dogs with dilated cardiomyopathy or chronic valvular disease
    AMERICAN JOURNAL OF VETERINARY RESEARCH
    
    S. Shahrara et al., "Upregulation of thyroid hormone receptor beta(1) and beta(2) messenger RNAin the myocardium of dogs with dilated cardiomyopathy or chronic valvular disease", AM J VET RE, 60(7), 1999, pp. 848-852
11. DRVOTA V; BLANGE I; HAGGBLAD J; SYLVEN C
    DESETHYLAMIODARONE PROLONGATION OF CARDIAC REPOLARIZATION IS DEPENDENT ON GENE-EXPRESSION - A NOVEL ANTIARRHYTHMIC MECHANISM
    Journal of cardiovascular pharmacology
    
    V. Drvota et al., "DESETHYLAMIODARONE PROLONGATION OF CARDIAC REPOLARIZATION IS DEPENDENT ON GENE-EXPRESSION - A NOVEL ANTIARRHYTHMIC MECHANISM", Journal of cardiovascular pharmacology, 32(4), 1998, pp. 654-661
12. DRVOTA V
    DOWN-REGULATION OF THYROID-HORMONE RECEPTOR SUBTYPE MESSENGER-RNA LEVELS BY RETINOIC ACID IN CULTURED CARDIOMYOCYTES
    Biochemical and biophysical research communications
    
    V. Drvota, "DOWN-REGULATION OF THYROID-HORMONE RECEPTOR SUBTYPE MESSENGER-RNA LEVELS BY RETINOIC ACID IN CULTURED CARDIOMYOCYTES", Biochemical and biophysical research communications, 242(3), 1998, pp. 593-596
13. Shahrara, S; Drvota, V; Blange, I; Torma, H; Sylven, C
    Characterization of AT-1 cardiomyocytes as a model for studies of T-3 effects on cardiac cells (vol 237, pg 303, 1997)
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
    
    S. Shahrara et al., "Characterization of AT-1 cardiomyocytes as a model for studies of T-3 effects on cardiac cells (vol 237, pg 303, 1997)", BIOC BIOP R, 253(1), 1998, pp. 192-192
14. BLANGE I; DRVOTA V; YEN PM; SYLVEN C
    SPECIES-DIFFERENCES IN CARDIAC THYROID-HORMONE RECEPTOR ISOFORMS PROTEIN ABUNDANCE
    Biological & pharmaceutical bulletin
    
    I. Blange et al., "SPECIES-DIFFERENCES IN CARDIAC THYROID-HORMONE RECEPTOR ISOFORMS PROTEIN ABUNDANCE", Biological & pharmaceutical bulletin, 20(11), 1997, pp. 1123-1126
15. BLANGE I; DRVOTA V; SYLVEN C
    SPECIES-DIFFERENCES IN CARDIAC THYROID-HORMONE RECEPTOR ISOFORMS PROTEIN ABUNDANCE
    The FASEB journal
    
    I. Blange et al., "SPECIES-DIFFERENCES IN CARDIAC THYROID-HORMONE RECEPTOR ISOFORMS PROTEIN ABUNDANCE", The FASEB journal, 11(9), 1997, pp. 327-327
16. DRVOTA V; BLANGE I; HOGGBLAD J; SYLVAN C
    DESETHYLAMIODARONE PROLONGATION OF CARDIAC REPOLARIZATION IS DEPENDENT ON GENE-EXPRESSION - A NOVEL ANTIARRHYTHMIC MECHANISM
    Circulation
    
    V. Drvota et al., "DESETHYLAMIODARONE PROLONGATION OF CARDIAC REPOLARIZATION IS DEPENDENT ON GENE-EXPRESSION - A NOVEL ANTIARRHYTHMIC MECHANISM", Circulation, 96(8), 1997, pp. 1623-1623
17. SHAHRARA S; DRVOTA V; BLANGE I; TORMA H; SYLVEN C
    CHARACTERIZATION OF AT-1 CARDIOMYOCYTES AS A MODEL FOR STUDIES OF T-3EFFECTS ON CARDIAC-CELLS
    Biochemical and biophysical research communications
    
    S. Shahrara et al., "CHARACTERIZATION OF AT-1 CARDIOMYOCYTES AS A MODEL FOR STUDIES OF T-3EFFECTS ON CARDIAC-CELLS", Biochemical and biophysical research communications, 237(2), 1997, pp. 303-306
18. DRVOTA V; CARLSSON B; HAGGBLAD J; SYLVEN C
    AMIODARONE IS A DOSE-DEPENDENT NONCOMPETITIVE AND COMPETITIVE INHIBITOR OF T3 BINDING TO THYROID-HORMONE RECEPTOR SUBTYPE BETA-1, WHEREAS DISOPYRAMIDE, LIGNOCAINE, PROPAFENONE, METOPROLOL, DL-SOTALOL, AND VERAPAMIL HAVE NO INHIBITORY EFFECT
    Journal of cardiovascular pharmacology
    
    V. Drvota et al., "AMIODARONE IS A DOSE-DEPENDENT NONCOMPETITIVE AND COMPETITIVE INHIBITOR OF T3 BINDING TO THYROID-HORMONE RECEPTOR SUBTYPE BETA-1, WHEREAS DISOPYRAMIDE, LIGNOCAINE, PROPAFENONE, METOPROLOL, DL-SOTALOL, AND VERAPAMIL HAVE NO INHIBITORY EFFECT", Journal of cardiovascular pharmacology, 26(2), 1995, pp. 222-226
19. DRVOTA V; BRONNEGARD M; HAGGBLAD J; SYLVEN C
    DOWN-REGULATION OF THYROID-HORMONE RECEPTOR SUBTYPE MESSENGER-RNA LEVELS BY AMIODARONE DURING CATECHOLAMINE STRESS IN-VITRO
    Circulation
    
    V. Drvota et al., "DOWN-REGULATION OF THYROID-HORMONE RECEPTOR SUBTYPE MESSENGER-RNA LEVELS BY AMIODARONE DURING CATECHOLAMINE STRESS IN-VITRO", Circulation, 92(8), 1995, pp. 2741-2741
20. DRVOTA V; BRONNEGARD M; HAGGBLAD J; BARKHEM T; SYLVEN C
    DOWN-REGULATION OF THYROID-HORMONE RECEPTOR SUBTYPE MESSENGER-RNA LEVELS BY AMIODARONE DURING CATECHOLAMINE STRESS IN-VITRO
    Biochemical and biophysical research communications
    
    V. Drvota et al., "DOWN-REGULATION OF THYROID-HORMONE RECEPTOR SUBTYPE MESSENGER-RNA LEVELS BY AMIODARONE DURING CATECHOLAMINE STRESS IN-VITRO", Biochemical and biophysical research communications, 211(3), 1995, pp. 991-996
21. DRVOTA V; JANSON A; NORMAN C; SYLVEN C; HAGGBLAD J; BRONNEGARD M; MARCUS C
    EVIDENCE FOR THE PRESENCE OF FUNCTIONAL THYROTROPIN RECEPTOR IN CARDIAC-MUSCLE
    Biochemical and biophysical research communications
    
    V. Drvota et al., "EVIDENCE FOR THE PRESENCE OF FUNCTIONAL THYROTROPIN RECEPTOR IN CARDIAC-MUSCLE", Biochemical and biophysical research communications, 211(2), 1995, pp. 426-431
22. DRVOTA V; WEI H; HAGGBLAD J; CARLSSON B; SYLVEN C
    BETA-ADRENERGIC-RECEPTOR FUNCTION IN CULTURED AT-1 CARDIOMYOCYTES
    Biochemical and biophysical research communications
    
    V. Drvota et al., "BETA-ADRENERGIC-RECEPTOR FUNCTION IN CULTURED AT-1 CARDIOMYOCYTES", Biochemical and biophysical research communications, 207(1), 1995, pp. 13-19
23. DRVOTA V; CARLSSON B; HAGGBLAD J; SYLVEN C
    AMIODARONE IS A DOSE-DEPENDENT COMPETITIVE AND NONCOMPETITIVE INHIBITOR OF T3 BINDING TO HUMAN THYROID-HORMONE RECEPTOR-BETA-1 WHEREAS DISOPYRAMIDE, LIGNOCAINE, PROPAFENONE, METOPROLOL, SOTALOL AND VERAPAMIL HAVE NO EFFECT
    Circulation
    
    V. Drvota et al., "AMIODARONE IS A DOSE-DEPENDENT COMPETITIVE AND NONCOMPETITIVE INHIBITOR OF T3 BINDING TO HUMAN THYROID-HORMONE RECEPTOR-BETA-1 WHEREAS DISOPYRAMIDE, LIGNOCAINE, PROPAFENONE, METOPROLOL, SOTALOL AND VERAPAMIL HAVE NO EFFECT", Circulation, 90(4), 1994, pp. 38-38
24. DRVOTA V; CARLSSON B; HAGGBLAD J; SYLVEN C
    AMIODARONE IS A DOSE-DEPENDENT COMPETITIVE AND NONCOMPETITIVE INHIBITOR OF T3 BINDING TO HUMAN THYROID-HORMONE RECEPTOR-BETA-1 WHEREAS DISOPYRAMIDE, LIGNOCAINE, PROPAFENONE, METOPROLOL, SOTALOL AND VERAPAMIL HAVE NO EFFECT
    Circulation
    
    V. Drvota et al., "AMIODARONE IS A DOSE-DEPENDENT COMPETITIVE AND NONCOMPETITIVE INHIBITOR OF T3 BINDING TO HUMAN THYROID-HORMONE RECEPTOR-BETA-1 WHEREAS DISOPYRAMIDE, LIGNOCAINE, PROPAFENONE, METOPROLOL, SOTALOL AND VERAPAMIL HAVE NO EFFECT", Circulation, 90(4), 1994, pp. 38-38